adjuvanted quadrivalent subunit influenza vaccine

The adjuvanted quadrivalent subunit influenza vaccine is an investigational biologic vaccine candidate designed for the prevention of seasonal influenza, particularly in older adults (aged 65 and older). Developed through a collaboration between the Henan Provincial Center for Disease Control and Prevention, Ab&B Bio-tech, and Yither Biotech, the vaccine utilizes a protein subunit platform containing purified hemagglutinin antigens from four influenza strains: two influenza A (H1N1 and H3N2) and two influenza B (Victoria and Yamagata lineages). It is formulated with an oil-in-water emulsion adjuvant, likely MF59, to enhance the immune response in the elderly population, who often exhibit immunosenescence. The vaccine is currently being evaluated in a Phase I clinical trial in China to assess its safety, tolerability, and immunogenicity compared to adjuvant-only and placebo controls.

Other names

quadrivalent subunit influenza vaccine (adjuvanted)